|Videos|December 25, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Artistic Roots and Caregiving: A Calendar Contest Winner’s Story
2
Experts Discuss New Advances in Bladder Cancer Following ESMO 2025
3
A Cancer Survivor Rethinks Cancer Ghosting
4
A Story of Staying Active After a Lung Cancer Diagnosis
5
